Clinical Trials Browser

INDUSTRY × Neoplasms × Mn-PyC3A × Clear all

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms